Atazanavir News and Research

RSS

Atazanavir, also known as Reyataz, is a type of medicine called a protease inhibitor (PI). PIs block protease, a protein that HIV needs to make more copies of itself. Atazanavir was approved by the FDA on June 20, 2003, for use with other antiretroviral medication in the treatment of HIV infection. This medicine does
not cure or prevent HIV infection or AIDS and
does not reduce the risk of passing the virus to
other people.

Antiviral drugs may be a new treatment strategy in the fight against Candida auris

Antiviral drugs can make antifungals work again.

25 May 2023

Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

Researchers presented an overview of factors influencing emerging infectious diseases. They also highlighted the importance of molecular dynamic (MD) simulations and molecular docking (MDO) analysis for combating these diseases.

17 Oct 2022

In silico studies identify potent plant metabolites capable of inhibiting SARS-CoV-2

In silico studies assess the binding efficacy of phytoconstituents against active sites of SARS-CoV-2.

16 Oct 2022

Dolutegravir-based regimen more effective for treating pregnant people with HIV-1

Dolutegravir-based antiretroviral therapies (ART) for HIV-1 are more effective for pregnant people than some other ART regimens commonly used in the U.S. and Europe, according to a study led by Harvard T.H. Chan School of Public Health researchers.

1 Sep 2022

HIV patients on antiretroviral treatment with protease inhibitors may have lower COVID-19 risk

A preliminary study to be presented at this year's European Congress of Clinical Microbiology & Infectious Diseases in Lisbon, Portugal (23-26 April), suggests that people living with HIV who are on antiretroviral treatment (ART) with protease inhibitors (PI), may have a lower risk of COVID-19 infection.

27 Mar 2022

Study finds atazanavir inhibits main SARS-CoV-2 protease

Research shows that ATV has different antiviral activity compared to PAXLOVID™, encouraging further research.

29 Nov 2021

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

Researchers review diverse computational methods for drug/inhibitor design and enzymes as potential targets for inhibitors to treat coronaviruses diseases.

12 Oct 2021

Does interferon therapy work in COVID-19?

A new study published on the preprint site medRxiv in May 2020 reports on the efficacy of interferons in treating COVID-19. The research could help evaluate the place of such therapy in the management of this disease.

2 Jun 2020

New drug delivery system could be a boon for those on a multi-drug regimen

Researchers from the University of North Carolina at Chapel Hill have developed a unique new multi-drug delivery system that could p-rove to be useful for persons who need to take several drugs in a day as part of a regimen.

23 Sep 2019

Natural antioxidant bilirubin may provide cardiovascular benefits

Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology study.

18 May 2018

New computational framework accurately predicts drug-drug and drug-food interactions

A Korean research team from KAIST developed a computational framework, DeepDDI, that accurately predicts and generates 86 types of drug-drug and drug-food interactions as outputs of human-readable sentences, which allows in-depth understanding of the drug-drug and drug-food interactions.

18 Apr 2018

FDA approves new treatment for all HCV genotypes 1-6

The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis.

3 Aug 2017

FDA approves new combo drug Mavyret for adults with Hepatitis C infection

Yesterday the U.S. Food and Drug Administration gave its approval to Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C infection. These patients are infected with the Hepatitis C virus (HCV) of genotypes 1-6 and are those that have not developed liver cirrhosis or those who have developed mild cirrhosis. The approval for Mavyret was given to AbbVie Inc.

3 Aug 2017

ARV drug atazanavir may have significant effects on infant development

The antiretroviral (ARV) drug atazanavir—sometimes included in treatments to prevent mother-to-child HIV transmission during pregnancy—may have small but significant effects on infant development, reports a study in the journal AIDS, official journal of the International AIDS Society.

23 Feb 2016

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

The Medicines Patent Pool today announced a new licensing agreement with AbbVie, a global biopharmaceutical company, that seeks to address future demands for HIV treatment Lopinavir/Ritonavir (LPV/r) in South Africa and across Africa. The agreement has been reached in particular to help ensure sustainability of long-term supply of LPV/r, the most widely used second-line HIV treatment in South Africa and across Africa.

18 Dec 2015

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

The Medicines Patent Pool today announced a collaboration with the University of Liverpool and a licence for the university's Solid Drug Nanoparticle (SDN) technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines.

30 Nov 2015

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Results from the first phase 3 HIV study to enroll only women show improved safety and efficacy of the drug Stribild over multi-pill antiretroviral drug regimens. The research was presented at ASM's 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

21 Sep 2015

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis.

23 Dec 2014

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014.

20 Nov 2014

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure

17 Jul 2014